ESC Congress 2017 In Review -- Main Edition - 19

ESC Congress 2017

In Review

Probability of Freedom from
Acute Coronary Syndrome

Figure 1. Primary Outcome: Major Coronary Events*
Anacetrapib

Placebo

1640 (10.8%)

1830 (11.8%)

Placebo

Rate Ratio 0.91 (0.85 to 0.97)
P = .004

Anacetrapib

2
Yera of Follow-Up

*Coronary death, myocardial infarction, or coronary revascularisation.
Reprinted from The New England Journal of Medicine, Landry MJ et al, Effects
of Anacetrapib in Patients with Atherosclerotic Vascular Disease. EPub 28
August 2017. Copyright © 2017 Massachusetts Medical Society. Reprinted with
permission from Massachusetts Medical Society.

For the individual components of the primary outcome
significant reductions were noted for MI, coronary death
or MI, coronary revascularisation, and major coronary
event (all P < .01) but not coronary death.
All lipid levels improved. HDL-C increased by 104%,
LDL-C decreased by 41% (direct method), and apolipoprotein B and non-HDL-C decreased by 18% each. The
absolute reduction in non-HDL-C was proportional to
the reduction in coronary death or MI.
No significant evidence of differential proportional
effects among 23 prespecified subgroup categories was
noted. Small reductions in risk of new-onset diabetes
mellitus were noted. There were no excess symptomatic
side effects with anacetrapib, although levels in adipose
tissue rose with continued treatment. There was also
no excess of mortality, cancer, or other serious adverse
events. There were small increases in blood pressure
and small reductions in kidney function.
Clinical outcomes will be followed for at least an
additional 2 years after the end of the treatment period
to assess longer-term safety, as well as efficacy.

Don't miss the key dates and deadlines
for all ESC scientific meetings
https://escol.escardio.org/MyESC

Official Peer-Reviewed Highlights From ESC Congress 2017

https://escol.escardio.org/MyESC

Table of Contents for the Digital Edition of ESC Congress 2017 In Review -- Main Edition